Health Awareness, Inc

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)4 trials
• Gout3 trials
• Colorectal cancer1 trial
• Obesity1 trial
• Osteoarthritis1 trial

Phase

• Phase 24 trials
• Phase 34 trials

Status

• Recruiting5 trials
• Active, not recruiting2 trials
• Completed2 trials

Lead sponsor

• Crystalys Therapeutics3 trials
• Regeneron Pharmaceuticals2 trials
• Boehringer Ingelheim1 trial
• Eccogene1 trial
• Guardant Health, Inc.1 trial
• and 1 more

Running trials

• Recruiting

  A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

  NCT07527910· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

  NCT07535034· Phase 2· Crystalys Therapeutics· Source

  Contact: Ronald Surowitz, MD

• Recruiting

  A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07288138· Phase 2· Eccogene· Source

  Contact: Eccogene Clinical Trials

• Recruiting

  A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

  NCT07089888· Phase 3· Crystalys Therapeutics· Source

  Contact: Ronald Surowitz, MD

• Recruiting

  A Study of Dotinurad Versus Allopurinol in Participants With Gout

  NCT07089875· Phase 3· Crystalys Therapeutics· Source

  Contact: Ronald Surowitz, MD

• Active, not recruiting

  A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  NCT05519475· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

  NCT04136002· Guardant Health, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gout3 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting

Closed trials

• Completed

  A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

  NCT06309992· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain

  NCT03081806· Phase 3· Techfields Pharma Co. Ltd· Source